4dmedical Ltd. · ASX:4DX
4dmedical — Investor Presentation (February 2025)
46 slides from 4dmedical's investor presentation, Feb 21, 2025
Slide 1: See beyond the structure
See beyond the structure 4DMedical Limited (ASX:4DX) Capital raise presentation 21 February 2025 Copyright ©4DMedical Limited 2025 Level 7, Melbourne Connect 700 Swanston Street Melbourne, Victoria 3053 Australia ABN 31 161 684 831 www.4dmedical.com
Slide 2: Disclaimer
Disclaimer Important notice and disclaimer No advice or recommendation The following important notice and disclaimer applies to this presentation and you are therefore advised to read this Nothing in this presentation constitutes legal, financial, financial product, investment, tax or other advice o
Slide 3: Disclaimer
Disclaimer The historical financial information for the Company contained in this presentation has been derived from the audited position at the date of this presentation and are subject to change without notice. Subject to law, the Company and its and consolidated annual financial statements of the
Slide 4: Disclaimer
Disclaimer Unless otherwise expressly stated in this presentation, the Lead Manager is acting as lead manager in respect of the Lead Manager Offers and in respect of the SPP on the terms of the Lead Manager Mandate and Underwriting Agreement, the key terms The Lead Manager and its affiliates are a f
Slide 5: Company updates and capital raising
Company updates and capital raising January 2025 ▪ U.S. FDA clearance for IQ-UIP, an AI-driven diagnostic tool designed to improve the diagnosis of Usual Interstitial Pneumonia (UIP), a key indicator of Interstitial Pulmonary Fibrosis (IPF), serving global market of US$4bn in 2024, expected to be US
Slide 6: Company highlights
Company highlights ▪ Proprietary XV Technology: Non-invasive, four-dimensional lung imaging technology that provides unparalleled insights into lung function Innovative Technology ▪ Differentiated from traditional imaging methods (e.g., X-ray, CT, MRI) by delivering detailed functional data, not jus
Slide 7: 4DMedical Overview
4DMedical Overview
Slide 8: Global respiratory diagnostic market valued at US$31.3 billion per annum
Global respiratory diagnostic market valued at US$31.31 billion per annum Four existing lung diagnostic technologies account for 99% of all lung tests: Country Spend Procedures ($USD) Expenditure (USD $B) U.S.A 13,716M 73.5M 20 Others 4,964M 59.8M Germany 2,678M 20.3M Japan 1,905M 22.8M 15 Procedure
Slide 9: Current lung diagnostics are failing us
Current lung diagnostics are failing us Lung health screening Unexplained dyspnoea Burn Pits & DRRD (COPD, silicosis, black lung, lung cancer) (shortness of breath) (Deployment-related Respiratory Disease) ▪ COPD – 4th largest cause of ▪ $12.2bn cost of breathlessness in Australia2 ▪ >6million servi
Slide 10: Ventilation Perfusion
Ventilation Perfusion playback 0.85x (14 breaths per minute) playback 0.48x (75 beats per minute) 4DMedical Limited (ASX:4DX) 21 February 2025
Slide 11: Comprehensive chest diagnostics product suite
Comprehensive chest diagnostics product suite CT LVAS 1 XV LVAS 1 CT:VQ 5 Pulmonary Hypertension XV Scanner^ VA Initiatives Assessment 1,4 Functional Coronary Lung Density Artery Analysis 1,4 Calcification 1 XV Technology Partnerships Lung Density Analysis — Lung Texture Inspiration 1,4 Analysis 2,4
Slide 12: A Complete Lung Health Solution
A Complete Lung Health Solution Pulmonary Function Pulmonary Structure Cardiovascular Total Solution XV LVAS®1,4 CAC1,2 Combined product Lung Density 1,2,4 Coronary Calcification/Heart Dynamic Ventilation Emphysema, HAA, Fissures suite Analysis (Fluoroscopy) Disease Enabling access to key imaging mo
Slide 13: Commercialisation strategy
Commercialisation strategy US Government US Commercial Global Partnerships Australia Enablers Olympus I-Med Exclusive Non-exclusive Genentech Jones Radiology Reimbursement Nuance/Aidoc/Blackford Integral Diagnostics Sector Veterans Affairs Community-based Clinics Global Pharma Companies Community Cl
Slide 14: Recent achievements and momentum validate commercialisation strategy
Recent achievements and momentum validate commercialisation strategy FDA approval and new contracts Philips ➢ Expansion of product suite with FDA ➢ Master Reseller approval for IQ-UIP Expansion in AU Agreement ➢ US Department of executed Defense continued US ➢ Qscan and Perth ➢ Implementation engage
Slide 15: Financials and operating metrics
Financials and operating metrics
Slide 16: 4DMedical SaaS revenue building momentum
4DMedical SaaS revenue building momentum 4DMedical SaaS revenue – 1H24 to 1H251 Underlying 1H25 v 2H24 growth up 16.5% 4DMedical SaaS revenue ($M AUD) +16.5% Underlying SaaS revenue growth of 10% refers to 3.5 revenue generated from SaaS contracts to radiology clinics and medical centres (AU and US)
Slide 17: SaaS revenue driven by growth in sites, scans and fees
4DMedical SaaS revenue building momentum, driven by increased fundamentals of layering growth in sites, scans and fees Sites are growing at 41% YoY basis, with Scan volumes per site growing taking scan volume growth to 77% YoY, layered with increased fee per scan in core XV Technology® Site growth –
Slide 18: VA and Philips opportunity
VA and Philips opportunity
Slide 19: VA opportunity
VA opportunity Veterans Affairs opportunity Progress to date Next steps • VA opportunity significant and • 4DMedical well positioned to urgent, with PACT Act expected provide screening services – • Onboarding multiple spend of US$280 Billion over 10 successful burn pits trial at outpatient Clinics t
Slide 20: US reimbursement – XV LVAS and CT LVAS
US reimbursement – XV LVAS® and CT LVAS 1 We addressed three key 2 We engaged with key 3 CMS reimbursement was components of industry bodies for approved reimbursement support and approval ✓ American Medical Association ✓ Clinical data Code – describing the procedure CPT Panel and Advisors demonstra
Slide 21: Philips reseller agreement
Philips reseller agreement The reseller agreement The opportunity • Philips has a long established and significant existing 1 partnership with both the VA and DoD, spanning 45 years • Philips & 4DMedical to work together to Background support the need for scalable, non-invasive • 50% of VA clinics u
Slide 22: Introduction to CT:VQ
Introduction to CT:VQ
Slide 23: CT:VQ has an immediate opportunity to displace NUC:VQ
CT:VQ has an $1.1B $2.6B immediate NUC:VQ – USA1 NUC:VQ - GLOBAL1 opportunity to displace NUC: VQ $1.9B $8.2B CTPA – USA1 CTPA – GLOBAL1 4DMedical Limited (ASX:4DX) 21 February 2025 1. Figures adapted from Frost and Sullivan Report 2020 USD $31.3 billion global spend annually (table) 24
Slide 24: NUC:VQ is plagued by logistical and technical challenges
SPECT (V) SPECT (Q) NUC:VQ is plagued by logistical and technical challenges • Nuclear VQ is slow, logistically complex, expensive & delivers low resolution results. • This multi-billion dollar procedure is ripe for disruption. 25
Slide 25: CT:VQ — Comparison to SPECT Ventilation and Perfusion
CT:VQ — Comparison to SPECT Ventilation and Perfusion CT:VQ images correlate to SPECT with superior image fidelity without logistical challenges SPECT (V) CT:VQ (V) SPECT (Q) CT:VQ (Q) 26 Product is for investigational/research use only in a clinical study, is not regulatory approved and is not avai
Slide 26: Existing technology plagued by logistical and technical challenges
Existing technology plagued by logistical and technical challenges NUCLEAR MEDICINE CT:VQ – PROVIDING ENHANCED CURRENT STATE PATIENT EXPERIENCE AND EFFICIENCIES HIGH-COST PROCEDURE CT:VQ FOCUSES ON ADDRESSING THREE CRITICAL ISSUES: 1 ENHANCED PHYSICIAN EXPERIENCE POOR RESOLUTION OF OUTPUTS 1. REDUCI
Slide 27: 2025 outlook
2025 outlook Research and Product US Government Development • Veterans Affairs • Department of Defense • CT:VQ FDA submission and approval • Federal and State Facilities • IQ-UIP FDA clearance activation and stakeholders • XV ScannerTM deployments generate clinical evidence and workflow gains Philip
Slide 28: Capital raising
Capital raising
Slide 29: Details of the Offer
Details of the Offer 4DMedical is raising up to ~A$12.5m via a Placement and Underwritten SPP • Single tranche non-underwritten placement to sophisticated, professional and institutional investors to raise up to approximately ~$5.5m (before costs) Placement (Placement) • Approximately 12.9 million n
Slide 30: Indicative Timetable
Indicative Timetable Indicative Placement and SPP timetable Event Date SPP record date Thursday, 20 February 2025 Announcement of Capital Raising Friday, 21 February 2025 SPP Opens Tuesday, 25 February 2025 Settlement of Placement Thursday, 27 February 2025 Allotment and normal trading of Placement
Slide 31: Executive team – experienced team with proven track record to deliver
Executive team – experienced team with proven track record to deliver Dr ANDREAS FOURAS PhD MATT TUCKER SIMON GLOVER Dr GREG MOGEL MD Managing Director and CEO Chief Commercial Officer Chief Financial Officer Chief Medical Officer Award-winning aerospace engineer and innovator Seasoned executive lea
Slide 32: Board of Directors – significant medical and commercial sector experience
Board of Directors – significant medical and commercial sector experience LIL BIANCHI Dr ANDREAS FOURAS PhD Dr ROBERT A. FIGLIN MD Managing Director and CEO Non-Executive Director Non-Executive Chair Chair, Audit & Risk Committee Award-winning aerospace engineer and innovator Globally recognised lea
Slide 33: Appendix A: Key Risks
Appendix A: Key Risks
Slide 34: Key Risks
Key Risks * The following summary is not intended to be an exhaustive list of the risk factors to which 4DMedical is exposed. The Directors consider that, on receipt of funds from the Offers, 4DMedical will have sufficient working capital to carry out its objectives. However, financial resources are
Slide 35: Key Risks
Key Risks The legislative framework in key countries may vary without notice and adversely impact 4DMedical’s operations and profitability. Failure by 4DMedical to comply with Changes in law legislative or regulatory requirements may result in compliance orders being issued against 4DMedical, financ
Slide 36: Key Risks
Key Risks The performance of 4DMedical will continue to be influenced by the overall condition of the economy in Australia and the jurisdictions in which it has operations and any Macroeconomic and deterioration in employment or economic growth could adversely affect 4DMedical’s business. Other soci
Slide 37: Appendix B: Key terms of UWA
Key terms of UWA B at senaeeytt
Slide 38: Key terms of UWA
Key terms of UWA 4DMedical has entered into an underwriting agreement with Bell Potter Securities Limited ACN 006 390 772 (Underwriter) in respect of the Offers (Underwriting Agreement) under which the Underwriter has agreed to underwrite the subscription of New Shares for an underwritten amount of
Slide 39: Key terms of UWA
Key terms of UWA • any of 4DMedical’s clinical trials or products being placed on clinical hold by the US FDA or other applicable government agency; • ASIC or any other person proposes to conduct any enquiry, investigation or proceedings, or to take any regulatory action or to seek any remedy, in co
Slide 40: Key terms of UWA
Key terms of UWA • there is introduced, or there is a public announcement of a proposal to introduce, into the Parliament of Australia or any of its States or Territories any Act or prospective Act or budget or the Reserve Bank of Australia or any Commonwealth or State authority adopts or announces
Slide 41: Key terms of UWA
Key terms of UWA • any of the following occur: • a director of 4DMedical is charged with an indictable offence; • any government agency commences any public proceedings against 4DMedical or any of the directors in their capacity as a director of 4DMedical, or announces that it intends to take such a
Slide 42: Key terms of UWA
Key terms of UWA • 4DMedical or a material subsidiary: • varies any term of the Constitution; • alters the issued capital or capital structure of 4DMedical other than in connection with the Offers, or as contemplated by the Offer Materials; or • disposes, attempts or agrees to dispose of a substanti
Slide 43: Key terms of UWA
Key terms of UWA • a prescribed occurrence in respect of 4DMedical occurs during the Offers, other than: • as contemplated by the Underwriting Agreement; or • 4DMedical issuing securities pursuant to the exercise or conversion of any security on issue or any employee incentive scheme in operation as
Slide 44: Appendix C: International Offer Restrictions
Appendix C: International Offer Retsrictions
Slide 45: International Offer Restrictions
International Offer Restrictions International Offer Restrictions This document does not constitute an offer of New Shares or New Options in any jurisdiction in which it would be unlawful. In particular, this document may not be distributed to any person, and the New Shares or New Options may not be
Slide 46: 4DMedical Limited (ASX:4DX) 21 February 2025
4DMedical Limited (ASX:4DX) 21 February 2025 Copyright © 4DMedical Limited 2025 Level 7, Melbourne Connect 700 Swanston Street Melbourne, Victoria 3053 Australia www.4dmedical.com ABN 31 161 684 831